MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'biosciences'. Sat, 03 Sep 2011 02:26:04 +0100 http://www.medworm.com/index.php?rid=5078033&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F4GCHU9DVWGQ%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Sanofi hired Anne Whitaker as president of its US pharmacuetical operations. Previously, she worked at GlaxoSmithKline, where she was senior vice president and business unit head for cardiovascular, metabolic and urology since 2009. She joined ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5078033 Fri, 29 Jul 2011 12:29:16 +0100 5078033 http://www.medworm.com/index.php?rid=5062499&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F_zpfd5XXIyY%2F Early next year, a drug for cystic fibrosis is expected to be reviewed by the FDA and it is a moment the Cystic Fibrosis Foundation has been waiting years to occur. The non-profit has invested $75 million and approval of the drug - which was developed by Vertex Pharmaceuticals with support from the foundation - would provide a new treatment for patients. And CFF will get a new revenue stream. Why? As Nature writes: CFF has a stake in the intellectual property underlying the drug and is entitled to royalties. So-called venture philanthropy is increasing among foundations, which are managing research projects, making funding dependent on projects reaching predetermined milestones and potentially reaping a return. They are also trying to keep control in the event obstacles emerge. Not surpris... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5062499 Mon, 25 Jul 2011 14:59:40 +0100 5062499 http://www.medworm.com/index.php?rid=4893915&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F4kemhBVPFZI%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that VeraxisHealth promoted Anthony Durso to senior director for strategic planning and client services. A 16-year marketing and sales veteran, he joined the medical education and communications firm in 2010 after running Elemental Consulting, a str... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4893915 Fri, 03 Jun 2011 12:05:51 +0100 4893915 http://www.medworm.com/index.php?rid=4489973&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FPtDNCERgXE4%2F Some medicines are the butt of jokes. But one small drugmaker hopes a medicine under development will make butts feel better. And with some newly raised cash, the end result could be the first drug approved specifically to treat hemorrhoids, an ailment that last year generated more than $77 million in sales for mostly over-the-counter salves. That’s up 30 percent from 2006, according to IMS Health. “There are no drugs out there approved for this right now and I can’t find any published clinical data to support the use of any over-the-counter product,” says Russ Ellison, ceo of Ventrus Bioscience, which plans to publish an early-stage trial shortly and recently launched an intial stock offering to fund a 400-patient study later this year. The compound works, he says,... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4489973 Thu, 17 Feb 2011 16:58:32 +0100 4489973 http://www.medworm.com/index.php?rid=4436942&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FFoD7p_TQbwc%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Qforma hired Ted Pine as vice president of business development. He was previously vice president of sales at openQ, which markets programs for key opinion leader management and compliance, and was senior director of strategic accounts at Leade... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4436942 Fri, 04 Feb 2011 13:11:44 +0100 4436942 http://www.medworm.com/index.php?rid=4433329&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FduD93FOfi9U%2F Patrick Soon-Shiong, a billionaire who cut a controversial profile in the pharmaceutical industry, has reemerged and purchased Vitality, a private company with a device designed to remind patients to take their meds. Known as GlowCaps, these use wireless technology that is housed in the cap to generate reminders and refill alerts in the form of phone calls, e-mails and ringtones, as well as usage reports for docs. The move reflects the ongoing preoccupation with patient adherence in the pharmaceutical industry. A recent report by the New England Healthcare Institute found that poor adherence costs the US as much as $290 billion a year in unnecessary health care spending (full disclosure: we are co-sponsoring a conference on this topic in May). In general, the weak economy has meant fewer p... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4433329 Thu, 03 Feb 2011 13:40:54 +0100 4433329 http://www.medworm.com/index.php?rid=4159505&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FVTV6k-WcgJY%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Seyfarth Shaw added Steven Lipman as of counsel to its Boston office. He spent 10 years with the US Patent & Trademark Office, rising from patent examiner to senior attorney for the Assistant Commissioner for Patents. He also served with t... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4159505 Fri, 12 Nov 2010 12:55:12 +0100 4159505 http://www.medworm.com/index.php?rid=4152275&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FeHHPLO-suSU%2F Starting in August 2009, the management team at Affymetrix noticed what they believe is a curious pattern - a growing number of sales reps and tech personnel were leaving to join Pacific Biosciences, a rival that also develops advanced analytical tools. And so Affymetrix has sued PacBio and 25 unnamed individuals for illegally soliciting at least 10 of its staffers, who allegedly signed confidentiality and non-solicitation agreements. “We believe that this hiring pattern may reflect a conspiracy between Pacific Biosciences and current and former Affymetrix employees to interfere with Affymetrix’s contractual relations with its employees and to cause a breach of their fiduciary duties to Affymetrix,” wrote Wendy Lazerson of the Bingham McCutchen law firm to Pacific Bioscie... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4152275 Tue, 09 Nov 2010 14:53:19 +0100 4152275 http://www.medworm.com/index.php?rid=3973117&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fb2h0UB6N-As%2F Rise and shine, everyone. Another day is upon us. But this is a good thing. As one of our favorite sages, the Morning Mayor, used to say: Every brand new day should be unwrapped like a precious gift. While you tug on the ribbon, we will brew the mandatory cup of stimulation and poke around for interesting items. Here, in fact, are a few to help you get started. Have a good one and stay in touch… Roche Rules Out Merging R&D With Genentech (Reuters) Abbott To Close Canadian Baby Formula Plant (Brockville Recorder & Times) China’s BGI And Merck Form Alliance (Bio-IT World) Abbott Fights To Keep Meridia Diet Pill On The Market (Reuters) K-V Pharmaceutical Secures A $20M Loan (Fox Business) Genentech CEO Resigns From Dendreon Board (Xconomy) Cell Therapeutics Appeals FDA R... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3973117 Wed, 15 Sep 2010 11:51:18 +0100 3973117 http://www.medworm.com/index.php?rid=3911869&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FGf8L4iGDbFc%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something that’s become a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that the AbelsonTaylor advertising agency that specializes in healthcare, promoted Barry Levine to creative director. A 19-year veteran of pharma advertising, he joined the agency in 1998, serving most recently as associate c... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3911869 Fri, 27 Aug 2010 12:25:59 +0100 3911869 http://www.medworm.com/index.php?rid=3666225&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FPxIkfIQXUvo%2F Good morning, everyone. Nice to see you again. Another shiny day here on the Pharmalot corporate campus, where we are recovering from the latest installment in our ‘Let’s See Them Before They Die‘ concert series. Accordingly, we are brewing multiple cups of stimulation. Meanwhile, here are a few items to help you get started yourselves. Hope your day goes well and catch you later… Sanofi-Aventis To Cut More Costs, Sales Force (Bloomberg News) Abbott And Neurocrine Sign Deal For Endometriosis Drug (Reuters) Cipla Signs Chinese Partner To Make Biosimilars (Bloomberg News) Sanofi-Aventis Buys Canderm Pharma (Montreal Gazette) The New World Order In R&D (InPharm) USDA Approves Vaccine For Dog Flu (Los Angeles Times) Amylin Stock Hit On Bydureon Data (Reuters) Pfize... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3666225 Wed, 16 Jun 2010 12:03:56 +0100 3666225 http://www.medworm.com/index.php?rid=3652690&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FnijjsaDZvoo%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something that’s become a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Pfizer hired Michael Ehlers as chief scientific officer for neuroscience research. Most recently, he was a Duke Univerity neurology professor and an investigator with the Howard Hughes Medical Institute. Ehlers also head... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3652690 Fri, 11 Jun 2010 12:10:27 +0100 3652690 http://www.medworm.com/index.php?rid=3254419&cid=t_232572_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2010%2F02%2Feverything-is-up-to-date-in-kansas-city.html They say everything is up to date in Kansas City, so maybe it should not be a surprise that it is the source of a new and colorful tale of how leaders of health care organizations are different from you and me.  The Kansas City Star reported about the professional life of the recently fired CEO of Kansas City University of Medicine and Biosciences:Hiring the CEOThere’s an often-told story about how Karen Pletz, the fired president of the Kansas City University of Medicine and Biosciences, got her job in the first place.On a flight from Phoenix to Kansas City in 1995, a stranger sat next to her: Jack Weaver, then chairman of the university’s board of trustees.Pletz, with a law degree and a career in banking, so impressed Weaver that he proposed she join the board. When the tru... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=3254419 Mon, 08 Feb 2010 22:43:00 +0100 3254419 http://www.medworm.com/index.php?rid=3244050&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FvsxrDoBSY9s%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something we hope to make a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Genzyme hired Lilly’s former head of manufacturing, Scott Canute, to run manufacturing and operations. He will be in charge of pulling rabbits out of hats, given Genzyme’s embarassing problems at a plant that... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3244050 Fri, 05 Feb 2010 12:50:14 +0100 3244050 http://www.medworm.com/index.php?rid=3035828&cid=t_232572_77_f&fid=37259&url=http%3A%2F%2Fwww.horizonpress.com%2Fblogger%2F2009%2F11%2Fselect-biosciences-conferences-2010.html January 20 - 21, 2010 Stem Cells World CongressSan Francisco, CA, USA Further information4th annual Stem Cells World Congress and exhibition. There will be two parallel tracks focused specifically on: (1) Stem Cells in Drug Discovery and Development and (2) Regenerative MedicineFebruary 11 - 12, 2010 Screening EuropeBarcelona, Spain Further information7th annual Screening Europe conference and exhibition, claimed to be the largest screening event in Europe with four conference rooms in 2010. Novel Screening Platforms and Drug Discovery Methods, High Content Screening, Fragment Based Screening, Label Free Screening, Enzymes as Drug Targets, Receptors as Drug TargetsSuggested reading: Biology BooksMarch 4 - 5, 2010 Advances in Synthetic BiologyLondon, UK Further information3rd annual Advance... Microbiology Blog: The weblog for microbiologists. blogs http://www.medworm.com/rss/comments.php?id=3035828 Fri, 27 Nov 2009 16:10:00 +0100 3035828 http://www.medworm.com/index.php?rid=2871608&cid=t_232572_87_f&fid=38368&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FDisruptiveWomenInHealthCare%2F%7E3%2FHa0wmbppsG4%2F Well – sadly it’s been one year since I have posted a blog with Disruptive Women in Healthcare so I really need to update you all on the fascinating science occurring in the genomics community. Shortly after I wrote my last blog in October 2008, I attended a meeting at one of our country’s finest scientific institutions– Cold Spring Harbor Laboratories – where some of the world’s foremost scientific discoveries have occurred. At this inaugural meeting entitled “Personal Genomes”, scientists discussed the tremendous potential for understanding the genome and translating this knowledge into our quest for the personalization of healthcare – yet at this meeting one year ago, we were acknowledging that we had sequenced less than a handful of genomes, the task at hand enorm... Disruptive Women in Health Care blogs http://www.medworm.com/rss/comments.php?id=2871608 Wed, 07 Oct 2009 11:05:33 +0100 2871608 http://www.medworm.com/index.php?rid=2092766&cid=t_232572_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2009%2F01%2Fattention-lab-directors-fda-is-coming.html I have been mentioning this several times to several VC firms and to several small companies. If your business plan or investment does not have a section devoted to getting FDA approval, you will soon see that business do 1 of 3 things.1. Be sold to a commercial lab who can get FDA approval quicker2. Become extinct3. Struggle to create a plan to attain FDA approval and be 6 months to 1 year later to launch.Why am I saying this today???? Did anyone look at the NY Times yesterday?Quest admits problems with the Vitamin D test???On Good Morning America Diane Sawyer said "I didn't know that the tests which my doctor ordered are not FDA approved"Translation: A huge amount of public demand on an already strapped organization to regulate and assure the quality of laboratory testing, just as they d... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=2092766 Fri, 09 Jan 2009 15:55:00 +0100 2092766 http://www.medworm.com/index.php?rid=2067894&cid=t_232572_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2008%2F12%2Fsherpas-batting-average-for-2008.html I make some pretty outlandish predictions on this blog, including Francis Collins will become director of the NIH.....I am not afraid to be wrong. If I see a trend or a problem, I call it. What has gotten people's attention is that I tend to be right more often than I am wrong....at least for now.....I start out every year with some of these predictions, so I figure, why not look at the one's I made last year in 2008As I looked into my magic 8-ball/Complete Genomics Scanner. Which came true? Here are the predictions:1. Jim Watson will die.Well, only a few base pairs off on this one. The legend Victor McKusick did pass, God rest his soul.....Damn that 10x coverage.2. Mark Cuban would buy the rights to 23andMe's genome database.....I knew he would do something dastardly.....only it was not g... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=2067894 Sat, 27 Dec 2008 19:51:00 +0100 2067894 http://www.medworm.com/index.php?rid=2035951&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F482685314%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something we hope to make a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Qforma, which traffics in analytics and predictive modeling, hired Kent Harris as senior vice president of sales, new business. He last worked as a regional manager for seven years at Organon Pharmaceuticals and began hi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2035951 Fri, 12 Dec 2008 12:50:51 +0100 2035951 http://www.medworm.com/index.php?rid=1939687&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F444405344%2F The constant stream of job cuts at large drugmakers is making Signum Biosciences’ search for new employees easier. “It gives us leverage in terms of negotiating salary,” Maxwell Stock, the biopharma’s president and chief operating officer, tells NJBiz. “If there’s a perception from a potential employee that things are tough (in the job market), the person will tend not to want to negotiate as hard as if the opposite was true. There’s also a wider range of talent out there.” Indeed, as big drugmakers continue to trim jobs, smaller biopharmaceutical makers and specialty pharma are benefiting from the downsizing, according to David Poling, director of state business operations at Aerotek, a staffing firm. “It’s a great time for smaller drug companies to strike,... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1939687 Thu, 06 Nov 2008 14:14:37 +0100 1939687 http://www.medworm.com/index.php?rid=1926685&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F437953333%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here’s a new approach we hope to make a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Ian Spatz, who is Merck’s vice president of global health policy and a fixture on the Washington DC scene, will be leaving the drugmaker at the end of the year. Knowledgeable, articulate and gracious, Spatz h... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1926685 Fri, 31 Oct 2008 11:35:14 +0100 1926685 http://www.medworm.com/index.php?rid=1871105&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F416720606%2F In an era where ceo compensation is hotly debated, one sport is keeping tabs on the overpaid, but not overworked. So proxy advisor Glass Lewis has come up with a list of the most eggregious examples that it calls ‘Pay Dirt,’ which focuses on “the best examples of boards and compensation committees that have failed in their fiduciary duty to link pay with performance.” The 42-page report slices and dices ceo pay and performance several ways, but we noticed that King Pharmaceuticals ceo Brian Markison shows up on the firm’s ranking of the S&P 500 Overpaid 25, a dubious distinction. To be specific, Brian ranked No. 23 with about $30.3 million in total compensation, while King stock fell about 36 percent and earnings per share growth plummeted nearly 37 perce... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1871105 Fri, 10 Oct 2008 11:46:25 +0100 1871105 http://www.medworm.com/index.php?rid=1686519&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F358334346%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Regado Biosciences hired David Mazzo as ceo and president; Telik hired Stefan Ryser as senior vp, corporate strategy; SciClone Pharmaceuticals hired Jeff Lange as vp business development; Watson Pharmaceuticals hired Clare Carmichael as senior vp of human resources; Oramed Pharmaceuticals named Harold Jacob to its board; Insmed named Jim Miller vp process development; EPIX ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1686519 Thu, 07 Aug 2008 12:02:16 +0100 1686519 http://www.medworm.com/index.php?rid=1603403&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F331631039%2F Merck, Lilly and Pfizer are teaming with PureTech Ventures, a venture capital firm, to create a new entity that will focus on drug-discovery methods in hopes of reducing the failure rate of clinical trials, The Wall Street Journal reports. The new firm will be called Enlight Biosciences and has $39 million in backing. Enlight is the only for-profit venture in which Merck or Lilly collaborates with its rivals, according to the paper. Barbara Dalton, Pfizer’s vp for venture capital at Pfizer, says she is was unaware of any other collaborations. The drugmakers maintain there are no competitive conflicts because they view the technologies Enlight seeks to develop, including advanced body-imaging methods, as “pre-competitive,” David Steinberg, Enlight’s ceo, tells the Jo... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1603403 Thu, 10 Jul 2008 10:57:45 +0100 1603403 http://www.medworm.com/index.php?rid=1594008&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F328825240%2F In striking the deal, the German company, which is one of the largest suppliers of dialysis services and products, gains control of one of the biggest makers of generic injectable drugs. APP, which is based in Illinois, is now the biggest supplier of the Heparin blood thinner heparin in the US, following the recall earlier by Baxter International in response to hundreds of cases of serious side effects. The acquisition gives Fresenius more than 100 patent-free products for hospital patients receiving cancer, intensive care and infection treatments as well as anesthetics. APP, by the way, is headed by Patrick Soon-Shiong (pictured above), who gained notoriety a couple of years ago with his other company, Abraxis BioSciences, which charged a very high price for a generic version of the Taxol... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1594008 Mon, 07 Jul 2008 12:09:35 +0100 1594008 http://www.medworm.com/index.php?rid=1480918&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F301201665%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs being announced each month. Despite downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Altus Pharmaceuticals named Georges Gemayel as ceo; Endo Pharmaceuticals named Blaine Davis as vp investor relations; Anavex Life Sciences added Alison Ayers to its board; Avant Immunotherapeutics named Anthony Marucci as interim ceo; Patheon hired Eric Evans as cfo; Icon hired Roger Toothaker as global vice president; Ardea Biosciences named John Bec... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1480918 Fri, 30 May 2008 11:46:55 +0100 1480918 http://www.medworm.com/index.php?rid=1356361&cid=t_232572_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2008%2F04%2Ft-minus-21-hours.html Till Navigenics Launch.......Stay Tuned!-Stevep.s. Congrats to Amy over at....oh wait...she hasn't started a blog yet ;) But in all seriousness, congratulations. Thanks to Jonathan at Tree of Life for leaking this...... (Source: Gene Sherpas: Personalized Medicine and You) Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=1356361 Tue, 08 Apr 2008 01:11:00 +0100 1356361 http://www.medworm.com/index.php?rid=1316793&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F255062240%2F A nosh, for those of you deficient in culinary indulgences, is another way of saying snack. And nosh, we must. You will, of course, relate to the analogy that there is much to chew on, yes? So grab a cup of something hot, or a bottle of something cold, and take a bite… The widower of a New Jersey woman who died while using the Nuvaring contraceptive is suing Schering-Plough and Organon Biosciences, which made the device. Robert Bozicev claims Nuvaring, which his wife used for six months, says she collapsed, had trouble breathing and died of a blood clot. His lawyer says she had no risk factors and was in good health. The suit charges known health risks were concealed. Pfizer is closing its Groton manufacturing facility and laying off 80 workers. “The facility has ceased operati... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1316793 Thu, 20 Mar 2008 19:12:03 +0100 1316793 http://www.medworm.com/index.php?rid=1261809&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F242276870%2F You read it here first. The drugmaker is undergoing a companywide downsizing today in the wake of its $14 billion acquisition of Organon Biosciences, which was completed last November. The number of jobs being eliminated isn’t clear - sources say the total numbers in the hundreds, and possibly much higher- and affects nearly all departments, including finance, marketing, research, information technology at multiple locations in New Jersey, where the drugmaker is based. A spokeswoman confirms that “a number” of jobs have been eliminated as a result of the “integration process,” but declined further comment. Layoffs were expected after the Organon deal, but the cutbacks were delayed, mostly due to the distraction caused by the ongoing controversy over the Vytor... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1261809 Wed, 27 Feb 2008 19:32:44 +0100 1261809 http://www.medworm.com/index.php?rid=1247999&cid=t_232572_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2008%2F02%2Fshaking-chills-houston-texas-and-1000.html I couldn't figure out whether I was hallucinating from the fevers or if the email I received from a reader was correct. He said "Could you explain this to me, from 350k now to 1k? How could this be"He was of course speaking about the PacBio (Like Pacific Sunwear/PacSun) technology and press release that Reuters put out there. Man why can't I get on Reuters at the drop of a hat?From the release" A California company predicts it will soon be able to sequence an entire human gene map in four minutes, for just $1,000.""It will change health care forever if it works," Hugh Martin, the chief executive officer of the company, said in a telephone interview on MondayMartin thinks Pacific Biosciences' new technology will be able to get a human genome done in about 4 minutes.Yes, my wonderful readers... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=1247999 Thu, 21 Feb 2008 17:46:00 +0100 1247999 http://www.medworm.com/index.php?rid=1225633&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F233763049%2F The teleconference call is under way but not much yet on Vytorin. As for the loss, the drugmaker cited accounting rules related to the purchase of Organon BioSciences. The loss amounted to $2.08 per share for the three months ended Dec. 31, compared with a profit of $182 million, or 12 cents per share, a year earlier. Without the accounting adjustments, Schering-Plough would have had a profit of 27 cents, compared with 24 cents expected by analysts, according to Thomson Financial. Revenue rose 40 percent to $3.72 billion from $2.65 billion a year ago and exceeding analyst estimates of $3.1 billion, and reported double-digit sales increases in each of its three segments, prescription pharmaceuticals, consumer health care and animal health. Organon was acquired in November for about $14.4 bi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1225633 Tue, 12 Feb 2008 13:15:32 +0100 1225633 http://www.medworm.com/index.php?rid=1219525&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F231854198%2F The drugmaker has announced a few organizational changes at its research operations and, while the recent acquistion of Organon Biosciences is cited as a prime reason, the moves come after weeks of mounting criticism over the handling of the Enhance trial for the Vytorin cholesterol med. First up is Jacqueline Elbonne, an eight-year Schering-Plough veteran, who is now a vp for global research quality, which means she will oversee the interplay between research and such activities as manufacturing, labs, clinical work and pharmacovigilance, while also meeting regulatory requirements. She now reports to Tom Koestler, executive vp and the president of the drugmaker’s research unit. No specific explanation is offered for the move. The Organon deal, however, is cited as the reason for the... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1219525 Fri, 08 Feb 2008 21:39:56 +0100 1219525 http://www.medworm.com/index.php?rid=1152854&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F217139871%2F The day is humming along nicely, isn’t it? We are especially pleased that our water supply has returned. To celebrate, we are cheering our good fortune with a cup of coffee and foraging for more interesting items. Please enjoy… Dendreon’s Provenge Vaccine Gets European Patent (Yahoo/AP) Wyeth Sells Upstate NY Plant To Akrimax Pharma (WCAX.com) Pozen Migraine Drug Passes Safety Study (Yahoo/AP) Forest Labs Beats Earnings Estimates (TheStreet.com) XenoPort, Glaxo Restless Leg Drug Works In Trial (Yahoo/Reuters) Neurocrine Biosciences CEO Gary Lyons Resigns (The Boston Globe) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1152854 Tue, 15 Jan 2008 17:31:24 +0100 1152854 http://www.medworm.com/index.php?rid=1094333&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F200266997%2F There is ice and a bit of snow covering most everything on the Pharmalot corporate campus this morning, making for a picturesque view outside our windows. And so here a few items as we skate toward the end of another week…. FDA Meets Today To Discuss Cold Meds With Phenylephrine (Yahoo/AP) EU Wants New Warnings On Pfizer’s Chantix (Yahoo/Reuters) Neurocrine Cuts 130 Jobs - Half Its Workforce (Yahoo/AP) Ligand Pharmaceuticals Cuts More Jobs (The San Diego Tribune) Novartis Updates Warnings On Exjade (Yahoo/Reuters) EMEA Recommends Withdrawal Of Novartis’ Prexige (CNN/Thomson Financial) FDA Expects To Toughen Coated-Stent Guidelines (The Wall Street Journal) EU Backs Teva’s Generic Form Of Cellcept (Yahoo/Reuters) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1094333 Fri, 14 Dec 2007 12:38:10 +0100 1094333 http://www.medworm.com/index.php?rid=1093206&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F199770992%2F The FDA wants more data about indiplon, which has been stalled for more than a year, and the news sent shares in Neurocrine Biosciences down nearly 45 percent this morning. The request comes six months after the company resubmitted its application for 5mg and 10mg doses. The FDA denied approval in May 2006 over issues with a 15mg dose, which was supposed to become a big seller. The earlier setbacks prompted Pfizer to scuttle its collaboration, which in turn forced Neurocrine to shrink its staff. But the company pushed ahead, meeting with agency officials last August to review their requirements. Now, the FDA wants additional clinical trial and preclinical study data. The requirements include an objective/subjective clinical trial in the elderly, a safety study, and preclinical study data e... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1093206 Thu, 13 Dec 2007 14:55:41 +0100 1093206 http://www.medworm.com/index.php?rid=1075152&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F196123427%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Here are some of the latest moves… Sentrx tapped Chris Metzler as director of quality standards; Neurochem said g’bye to Phil Calais, who headed global business; Ambrilia Biopharma hires Phil Calais as its new ceo and president; InforMedix tapped Bruce Kneeland as vp for pharmacy product leasing; Rosetta Genomics named Ronen Tamir as exec vp, marketing and communication; Intranasal Therapeutics named Kathleen Boziwick as vp, commercial development; Intranasal Therapeutics hired Mike Lusty as vp... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1075152 Thu, 06 Dec 2007 15:01:28 +0100 1075152 http://www.medworm.com/index.php?rid=845907&cid=t_232572_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F152939026%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Here are some of the latest moves… Endo Pharmaceuticals appoints Nancy Wysenski as chief operating officer; Nitec Pharma appointed Anders Harfstrand as ceo and Andrea Buscaglia as cfo; ResMed named Kieran Gallahue as ceo; CryoCath Technologies added Jesse Penn to its board of directors; Prestwick Pharmaceuticals hired Marty Stogniew as executive vp, chief technology officer; Hana Biosciences named S. Michael Imperiale vp, clinical research and operations; EyeGate Pharma appointed Paul Chaney, exec vp... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=845907 Thu, 06 Sep 2007 11:17:18 +0100 845907 http://www.medworm.com/index.php?rid=728732&cid=t_232572_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F03%2F15%2Forganon-and-pharmacopeia-enter-into-alliance%2F This is old news from back in Feb but given the recent announcement of acquisition by Schering-Plough I thought it worth commenting on. PharmaLive: Organon and Pharmacopeia Enter Into Discovery, Development and Commercialization Alliance : It will be interesting to see what comes out of this agreement now that Schering-Plough will be making the calls once the merger is approved later this year. I don’t know that Schering-Ploug will want to continue with Pharmacopeia but I could be mistaken. I certainly don’t think SP wants to co-develop and co-commercialize future drugs with Pharmacopeia. Some times agreements such as these can be impediments to acquisitions but I personally think the deal/agreement route is better than the straight acquisition. However these agreements can als... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728732 Thu, 15 Mar 2007 15:31:57 +0100 728732 http://www.medworm.com/index.php?rid=728738&cid=t_232572_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F03%2F12%2Fanother-major-merger-schering-plough-to-acquire-organon-biosciences-for-144-billion%2F An another major merger, Schering-Plough is acquiring Organon Biosciences, the animal and human health business of Akzo Nobel for $14.4 Billion. PharmaLive: Schering-Plough to Acquire Organon BioSciences Schering think this will be a good addition to their pipeline and the deal is excepted to close before the end of this year. The Organon website is pretty vague on the number and kinds of products in its pipeline so it is hard to judge without further research. They say they have products at various stages including several in pate stage development. They have the plan to fill at least one new major product each year for the next few years. As you can see, it is pretty lacking of details. They do mention two products; asenapine for treatment of bipolar and schizophrenia and sugammadex used... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728738 Mon, 12 Mar 2007 19:36:03 +0100 728738